A settlement matrix in the new Dupixent drug-injury MDL would likely rank each claim by injury severity and proof strength. Advanced cutaneous T-cell lymphoma (CTCL), a skin lymphoma, with longer Dupixent use and complete records would sit in higher, better-paid tiers. An MDL moves similar federal lawsuits to one judge, and Dupixent is the brand name for dupilumab.
TorHoerman Law reports the panel created MDL No. 3180 in New Jersey before Judge Zahid N. Quraishi with 15 actions on June 4, 2026 MDL guide. A matrix would not set flat awards for every claimant.
Official resources:
- Read the original report from Atumio — Use this primary source to review the complete report.
- Read the official notice from Lawsuitwatch — Use this primary source to verify the official announcement.
Table of Contents
- Which lawsuits make up the new MDL?
- How would a tiered matrix divide payments?
- What would place a Dupixent claim in a higher tier?
- What would lower a claim's tier?
- What records should potential claimants keep now?
Which lawsuits make up the new MDL?
LawsuitWatch.ai reports plaintiffs in 15 cases across 12 federal districts asked for consolidation on February 13, 2026 over CTCL allegedly caused or accelerated by Dupixent timeline report. The request framed CTCL as the signature injury for centralization. The suits name Regeneron and Sanofi and allege failure to warn that Dupixent could cause or unmask CTCL first treated as eczema.
LawsuitWatch.ai identifies the pool as eczema, atopic-dermatitis and asthma patients prescribed dupilumab. The sequence began with an October 1, 2025 wrongful-death filing, Richardson v. Regeneron, in the Middle District of Tennessee.
How would a tiered matrix divide payments?
HarmReport explains that typical MDL global settlements use a tiered matrix based on injury severity, product-use duration, plaintiff age and quality of medical documentation, with different tiers paid different amounts how MDLs work. Each case is placed, not individually negotiated.
Mass-tort funds divide a fixed aggregate sum through points for injury severity and duration, strength of medical evidence and individual damages, according to SJKP Law. Strong, well-documented injuries earn more points than weak or thinly documented claims. Mainor Wirth describes the same model in the October 2024 Becton Dickinson agreement to resolve about 38,000 Bard hernia-mesh suits expected to exceed $1 billion through tiered points-based payouts tied to documented severity mesh lawsuit report.
What would place a Dupixent claim in a higher tier?
Diagnosis and treatment intensity would drive value most, according to the Fob James Law Firm analysis. Pathology proof of CTCL and aggressive care would outweigh a prescription alone.
Plaintiff age and individual economic loss would also enter the formula. Complete records let reviewers confirm each element without discounting for gaps.
- Biopsy-proven CTCL pathology with stage and subtype stated
- Systemic treatment, surgery, radiation or stem-cell transplant
- Hospital stays, specialist care and large medical bills
- Long, continuous Dupixent use shown by pharmacy records
- Clear timeline from eczema treatment to lymphoma diagnosis
What would lower a claim's tier?
Short Dupixent use, missing pharmacy records and mild skin disease with limited treatment would point toward lower tiers. Gaps between alleged injury and diagnosis would also reduce points. Thin pathology or an unclear distinction between prior eczema and later lymphoma would weaken causation proof.
Atumio reports the makers dispute causation and no court has decided whether Dupixent causes lymphoma. That dispute makes contemporaneous records matter more. A clean sequence of eczema diagnosis, Dupixent prescription, persistent symptoms and biopsy would support a higher placement than a delayed or inconsistent history.
What records should potential claimants keep now?
Preserve pathology reports, surgery and treatment records, bills and proof of Dupixent use and duration. Those four groups map directly to severity, duration, damages and medical proof. Ask the pharmacy for a complete dupilumab dispensing history and keep the original pathology lab name for possible slide review.
- Keep biopsy reports, staging studies and second opinions
- Save infusion or injection logs and pharmacy printouts
- File hospital, dermatology and oncology notes together
- Track bills, travel costs and lost work with dates
You Might Also Like
- A Wildfire Allegedly Started by Utility Equipment: How Do Lawyers Evaluate Settlement Value and Trial Risk?
- A Wastewater Discharge Causing a Fish Kill: How Do Lawyers Evaluate Settlement Value and Trial Risk?
- A Pipeline Explosion Following Corrosion Warnings: How Do Lawyers Evaluate Settlement Value and Trial Risk?